RxDoctor Payments Data

Linda Burstynowicz, MD

Internal Medicine · Grindstone, PANPI 1508866658

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 86 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$285
  • Radius Health, Inc.$144
  • Pfizer$133
  • AstraZeneca$124
  • Lilly USA, LLC$88
  • Amgen$87
  • plus $521 from 13 others

What the payments were for

  • Food & beverage$1,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,383 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,015
Medicare patients
165
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$105,468
XareltoRivaroxaban56$56,608
TrulicityDulaglutide55$54,133
JardianceEmpagliflozin28$34,316
FarxigaDapagliflozin Propanediol25$28,060
JanuviaSitagliptin Phosphate14$22,031
OzempicSemaglutide23$21,541
TradjentaLinagliptin21$20,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,200
Tresiba Flextouch U-200Insulin Degludec15$19,908
Incruse ElliptaUmeclidinium Bromide16$9,854
Breo ElliptaFluticasone/Vilanterol16$9,526
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,487
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$5,143
Atorvastatin Calcium496$4,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$105,468110 claims
Johnson & JohnsonXarelto$81$56,60856 claims
Boehringer IngelheimJardiance, Tradjenta$26$54,70749 claims
Lilly USA, LLCTrulicity$88$54,13355 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$39$39,58058 claims
AstraZenecaFarxiga$124$28,06025 claims
MerckJanuvia$19$22,03114 claims
Novo NordiskOzempic$285$21,54123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Grindstone

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →